SAN DIEGO, June 02, 2025 -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the...
Arthur Klausner to speak at FundingPost's early-stage VC breakfast in New York City on May 18
News | 05. 18. 2006
